Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: Do combination tests improve detection?

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 10, 2004, Pages 1640-1645

  Etzioni, Ruth ^a   Falcon, Seth ^a   Gann, Peter H ^b   Kooperberg, Charles L ^a   Penson, David F ^c   Stampfer, Meir J ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

AGED; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 4944237212     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
2. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
3. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-42.
4. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
5. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996;48:55-61.
6. Gann PH, Ma J, Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002;167:2427-34.
7. Brawer MK, Cheli CD, Neaman IE, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000;163:1476-80.
8. Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000;163:119-26.
9. Etzioni R, Urban N, Ramsey SD, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
10. Pepe MS. The statistical evaluation of medical tests for classification and prediction. New York: Oxford University Press; 2003.
11. Etzioni R, Kooperberg C, Pepe MS, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003;4:523-38.
12. Baker SG. Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics 2000;56:1082-7.
13. Ruczinski I, Kooperberg C, LeBlanc ML. Logic regression. J Comput Graph Stat 2003;12:475-511.
14. Dodd LE, Pepe MS. Semiparametric regression for the area under the receiver operating characteristic curve. J Am Stat Assoc 2003;98:409-17.
15. Partin AW, Brawer MK, Subong EN, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998;1:197-203.
16. Okihara K, Cheli CD, Partin AW, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002;167:2017-23; discussion 23-4.
17. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
18. Reissigl A, Klocker H, Pointner J, et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996;48:62-6.